N. C. Tebbutt

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu et al. · The Lancet Oncology · 2020 · 567 citations

Medicine, Oncology, Pharmacology +14

ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG

N. C. Tebbutt, T. Sourjina, A. H. Strickland et al. · Journal of Clinical Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +17

YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)

Antonio Cubillo Gracián, Andrew Dean, Andrés Muñoz et al. · Annals of Oncology · 2017 · 24 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

An analysis of the outcomes of treatment of small cell lung cancer in the elderly

N. C. Tebbutt, R. Snyder, W. Ivon Burns · Australian and New Zealand Journal of Medicine · 1997 · 22 citations

Medicine, Geriatric Medicine, Oncology +12

Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response

Shelly Sud, Christopher O’Callaghan, Caleb Jonker et al. · Current Oncology · 2018 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +17